Literature DB >> 36161339

Adjusting conventional FRAX estimates of fracture probability according to the number of prior fractures.

John A Kanis1,2,3, Helena Johansson4,5, Nicholas C Harvey6,7, Vilmundur Gudnason8,9, Gunnar Sigurdsson8, Kristin Siggeirsdottir8, Mattias Lorentzon4,10, Enwu Liu4, Liesbeth Vandenput4,11, Eugene V McCloskey5,12.   

Abstract

The risk of a recurrent fragility fracture is high following a first fracture and higher still with more than one prior fracture. This study provides adjustments to FRAX-based fracture probabilities accounting for the number of prior fractures.
INTRODUCTION: Prior fractures increase subsequent fracture risk. The aim of this study was to quantify the effect of the number of prior fractures on the 10-year probability of fracture determined with FRAX®.
METHODS: The study used data from the Reykjavik Study fracture register that documented prospectively all fractures at all skeletal sites in a large sample of the population of Iceland. Ten-year probabilities of hip fracture and major osteoporotic fracture (MOF) were determined according to the number of prior osteoporotic fractures over a 20-year interval from the hazards of death and fracture. Fracture probabilities were also computed for a prior osteoporotic fracture irrespective of the number of previous fractures. The probability ratios provided adjustments to conventional FRAX estimates of fracture probability according to the number of prior fractures.
RESULTS: Probability ratios to adjust 10-year FRAX probabilities of a hip fracture and MOF increased with the number of prior fractures but decreased with age in both men and women. Probability ratios were similar in men and women and for hip fracture and MOF. Mean probability ratios according to the number of prior fractures for all scenarios were 0.95, 1.08, 1.21 and 1.35, for 1,2, 3 and 4 or more prior fractures, respectively. Thus, a simple rule of thumb is to downward adjust FRAX-based fracture probabilities by 5% in the presence of a single prior fracture and to uplift probabilities by 10, 20 and 30% with a history of 2, 3 and 4 or more prior fractures, respectively.
CONCLUSION: The probability ratios provide adjustments to conventional FRAX estimates of fracture probability according to the number of prior fractures.
© 2022. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.

Entities:  

Keywords:  FRAX adjustment; Fracture probability; Prior fracture; Risk assessment

Year:  2022        PMID: 36161339     DOI: 10.1007/s00198-022-06550-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   5.071


  3 in total

Review 1.  UK clinical guideline for the prevention and treatment of osteoporosis.

Authors:  Celia L Gregson; David J Armstrong; Jean Bowden; Cyrus Cooper; John Edwards; Neil J L Gittoes; Nicholas Harvey; John Kanis; Sarah Leyland; Rebecca Low; Eugene McCloskey; Katie Moss; Jane Parker; Zoe Paskins; Kenneth Poole; David M Reid; Mike Stone; Julia Thomson; Nic Vine; Juliet Compston
Journal:  Arch Osteoporos       Date:  2022-04-05       Impact factor: 2.879

Review 2.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

3.  Worldwide uptake of FRAX.

Authors:  J A Kanis; H Johansson; A Oden; C Cooper; E V McCloskey
Journal:  Arch Osteoporos       Date:  2014-01-14       Impact factor: 2.617

  3 in total
  1 in total

1.  Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.

Authors:  Bente Langdahl; Lorenz C Hofbauer; Serge Ferrari; Zhenxun Wang; Astrid Fahrleitner-Pammer; Evelien Gielen; Péter Lakatos; Edward Czerwinski; Esteban Jódar Gimeno; Jen Timoshanko; Mary Oates; Cesar Libanati
Journal:  Osteoporos Int       Date:  2022-09-29       Impact factor: 5.071

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.